Bio Path Holdings Stock Alpha and Beta Analysis
| BPTH Stock | USD 0.80 0.02 2.44% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bio Path Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bio Path over a specified time horizon. Remember, high Bio Path's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bio Path's market risk premium analysis include:
Beta (0.07) | Alpha (0.41) | Risk 6.61 | Sharpe Ratio (0.02) | Expected Return (0.11) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Bio |
Bio Path Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bio Path market risk premium is the additional return an investor will receive from holding Bio Path long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bio Path. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bio Path's performance over market.| α | -0.41 | β | -0.07 |
Bio Path expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Bio Path's Buy-and-hold return. Our buy-and-hold chart shows how Bio Path performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Bio Path Market Price Analysis
Market price analysis indicators help investors to evaluate how Bio Path stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bio Path shares will generate the highest return on investment. By understating and applying Bio Path stock market price indicators, traders can identify Bio Path position entry and exit signals to maximize returns.
Bio Path Return and Market Media
The median price of Bio Path for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 0.97 with a coefficient of variation of 11.44. The daily time series for the period is distributed with a sample standard deviation of 0.11, arithmetic mean of 0.97, and mean deviation of 0.09. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Aubert Paul of 10000 shares of Bio Path subject to Rule 16b-3 | 09/10/2024 |
2 | Acquisition by Sherwood Aline of 2000 shares of Bio Path at 1.55 subject to Rule 16b-3 | 09/30/2024 |
3 | Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity | 10/08/2024 |
4 | Bio-Path Holdings Announces 4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 10/09/2024 |
5 | Bio-Path Holdings Announces Closing of 4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 10/10/2024 |
6 | Acquisition by Cleaver Heath of 2000 shares of Bio Path at 1.55 subject to Rule 16b-3 | 10/29/2024 |
7 | Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024 | 11/08/2024 |
8 | Acquisition by Garrison Thomas E of 400000 shares of Bio Path at 1.5 subject to Rule 16b-3 | 11/11/2024 |
9 | Short Interest in Bio-Path Holdings, Inc. Drops By 80.0 | 11/13/2024 |
10 | Bio-Path GAAP EPS of -0.70 | 11/15/2024 |
11 | Antisense and RNAi Therapeutics Market Research Report 2024 Global Market to Reach 3.6 Billion by 2030 - Investments in RNA-Based Research Expands the Market fo... | 11/19/2024 |
12 | Bio-Path Could Find a Support Soon, Heres Why You Should Buy the Stock Now | 11/20/2024 |
13 | Disposition of 25000 shares by Garrison Michael J. of Bio Path at 0. subject to Rule 16b-3 | 11/22/2024 |
About Bio Path Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bio or other stocks. Alpha measures the amount that position in Bio Path Holdings has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 1.52 | 0.27 | 0.39 | 0.37 | Days Of Inventory On Hand | 1.19 | 7.36 | 8.46 | 8.04 |
Bio Path Upcoming Company Events
As portrayed in its financial statements, the presentation of Bio Path's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bio Path's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Bio Path's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Bio Path. Please utilize our Beneish M Score to check the likelihood of Bio Path's management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Bio Path
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Bio Path Backtesting, Bio Path Valuation, Bio Path Correlation, Bio Path Hype Analysis, Bio Path Volatility, Bio Path History and analyze Bio Path Performance. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Bio Path technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.